Syndax Pharma 
Welcome,         Profile    Billing    Logout  
 3 Products   253 Diseases   3 Products   45 Trials   1655 News 


12345678910111213...2122»
  • ||||||||||  Review, Journal:  Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD. (Pubmed Central) -  Sep 27, 2024   
    Bronchiolitis obliterans syndrome (BOS) still represents a challenge; among the compounds targeting non-immune effectors, Alvelestat, a Neutrophil elastase inhibitor, seems promising in BOS. Finally, in both aGVHD and cGVHD, the association of biological markers with specific disease manifestations could help refine risk stratification and the availability of reliable biomarkers for specific treatments.
  • ||||||||||  Niktimvo (axatilimab-csfr) / Syndax Pharma, Incyte
    CSF-1R Inhibitor (Axatilimab) for Chronic GVHD (Room B (2F)) -  Sep 24, 2024 - Abstract #ICBMT2024ICBMT_186;    
    Responses were not influenced by the extent of cGVHD involvement at baseline organ, number of received prior lines of treatment (including use of ruxolitinib, ibrutinib or belumosudil), and were seen across all organs, including sclerotic manifestation such as joints and fascia, esophagus, lung, and skin. Targeting CSF-1R
  • ||||||||||  Review, Journal, Epigenetic controller:  Role of histone deacetylases and their inhibitors in neurological diseases. (Pubmed Central) -  Sep 21, 2024   
    Additionally, the current pharmacological situation, problems, and developmental prospects of HDAC inhibitors are described. A better understanding of the pathogenic mechanisms of HDACs in the nervous system may reveal new targets for therapeutic interventions in diseases and help to relieve healthcare pressure through preventive measures.
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Journal:  Development of new pyrazoles as class I HDAC inhibitors: Synthesis, molecular modeling, and biological characterization in leukemia cells. (Pubmed Central) -  Sep 20, 2024   
    Compounds 12b, 15b, and 15i were found to be potent HDAC1 inhibitors, also in comparison to the reference compounds entinostat and tacedinaline, with IC50 values of 0.93, 0.22, and 0.68??M, respectively...In addition, we studied the interaction of the compounds with HDAC subtypes using docking and molecular dynamic simulations. In summary, we have developed a new chemotype of HDAC1 inhibitors that can be used for further structure-based optimization.
  • ||||||||||  elimusertib (BAY 1895344) / Bayer, cisplatin / Generic mfg., Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Journal:  SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells. (Pubmed Central) -  Sep 18, 2024   
    HDAC inhibition using entinostat returned an epigenetic downregulation of SLFN11 in W1CR cells, caused SLFN11 re-expression and re-sensitized these cells to cisplatin...In contrast, inhibition of the DNA damage repair master regulator ATR using sub-toxic concentrations of elimusertib sensitized parental cell lines as well as intrinsically resistant EFO21 cells to cisplatin, and fully reversed acquired cisplatin resistance in cisplatin-adapted sublines W1CR, A2780cis, and KuramochirCDDP2000...In conclusion, SLFN11 and ATR are involved in ovarian cancer cisplatin resistance. Although our data identify ATR as key target for tackling cisplatin resistance in ovarian cancer, future studies are needed to identify biomarkers that indicate, which individual ovarian cancers benefit from SLFN11 re-activation and/or ATR inhibition.
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Journal:  Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors. (Pubmed Central) -  Sep 7, 2024   
    P2
    JNJ-75276617 demonstrated synergistic effects with gilteritinib in In the treatment of relapsed or refractory abdominal NETs, entinostat 5 mg weekly led to prolonged SD and reduced the rate of tumor growth by 32% to 83% with an acceptable safety profile (ClinicalTrials.gov Identifier: NCT03211988).
  • ||||||||||  Niktimvo (axatilimab-csfr) / Syndax Pharma, Incyte
    Efficacy of Axatilimab in the Management of Refractory Chronic Graft-Versus-Host Disease (LEVEL 3, HALL B3) -  Aug 30, 2024 - Abstract #SOHO2024SOHO_967;    
    In this systematic review, axatilimab exhibits promising therapeutic outcomes for refractory cGVHD and an acceptable safety profile based on the findings from phase 1 and phase 2 clinical trials. However, prospective clinical trials with randomization are needed to consolidate these findings.
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Journal:  Co-delivery Nano System of MS-275 and V-9302 Induces Pyroptosis and Enhances Anti-Tumor Immunity Against Uveal Melanoma. (Pubmed Central) -  Aug 21, 2024   
    When combined with programmed cell death protein 1 monoclonal antibodies (?-PD-1), these NPs facilitate immune cell infiltration, improving anti-tumor immunity, converting "immune-cold" tumors into "immune-hot" tumors, and enhancing immune memory in mice. The findings present a nano-delivery strategy for the co-delivery of epigenetic therapeutics and metabolic inhibitors, which induces pyroptosis in tumors cells and improves the effectiveness of chemotherapy and immunotherapy.
  • ||||||||||  revumenib (SNDX-5613) / Syndax Pharma
    Journal:  Revumenib for patients with acute leukemia: a new tool for differentiation therapy. (Pubmed Central) -  Aug 1, 2024   
    It will focus on the pathophysiology of leukemias sensitive to menin inhibition, delineation of how this understanding led to targeted drug development, and data from clinical trials. The important discovery of resistance mechanisms will also be explored, as well as future directions in using menin inhibitors for treating leukemia.
  • ||||||||||  Epidaza (chidamide) / Chipscreen, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Journal:  Enhancing anti-cancer capacity: Novel class I/II HDAC inhibitors modulate EMT, cell cycle, and apoptosis pathways. (Pubmed Central) -  Jun 28, 2024   
    Various biological functional assays evidenced that two of these compounds could suppress cancer growth and migration capacity, through regulating epithelial-mesenchymal transition (EMT), cell cycle, and apoptosis mechanisms. Data from 3D cancer cells and the in vivo zebrafish model suggested the potential of these compounds in cancer therapy in the future.
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    P1 data, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases:  Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. (Pubmed Central) -  Jun 26, 2024   
    P1
    Exploratory analyses revealed that changes in myeloid cells may contribute to responses; however, no correlation was noted between changes in CD8:FoxP3 ratio, PD-L1 status and tumor mutational burden and response. These findings support further investigation of this treatment in a phase II trial.
  • ||||||||||  pinometostat (EPZ-5676) / Ipsen, revumenib (SNDX-5613) / Syndax Pharma
    Journal:  Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia. (Pubmed Central) -  Jun 19, 2024   
    Finally, we demonstrate significant synergy between revumenib and the DOT1L inhibitor pinometostat in KMT2A-rearranged ALL, suggesting that such drug combinations represent a potent therapeutic strategy for these patients. Collectively, our findings underscore the complexity of resistance mechanisms and advocate for precise patient stratification to optimize the use of menin inhibitors in KMT2A-rearranged acute leukemia.
  • ||||||||||  Epidaza (chidamide) / Chipscreen, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Journal:  Breast cancer epigenetics: current and evolving treatment. (Pubmed Central) -  Jun 11, 2024   
    Our study contributes to the understanding of the signaling mechanisms underlying maternal subclinical hypothyroidism-mediated cognitive impairment in the offspring. This study highlights the growing interest in BC epigenetics, suggesting a potential shift from a one-size-fits-all approach to precision medicine, and emphasizes the necessity for robust evidence on their efficacy and safety to support continuous development and approval, addressing the unmet needs in BC treatment.
  • ||||||||||  Beleodaq (belinostat) / Aurobindo, Assertio, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    UNCOVERING THE POTENTIAL OF THE PA2G4-MYC AXIS AS A TARGET IN 3Q26 ACUTE MYELOID LEUKEMIA (Hall Goya 2) -  May 15, 2024 - Abstract #EHA2024EHA_3601;    
    We advocate for a clinical treatment approach that harnesses the ability of HDACis tosuppress EVI1 in 3q26 AML patients. Additionally, our findings highlight PA2G4 as a potential therapeutictarget for 3q26 AML patients and urge the development of PA2G4-MYC-EVI1 complex disruptors in this AMLsubtype.
  • ||||||||||  axatilimab (SNDX-6352) / Syndax Pharma, Incyte
    AXATILIMAB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: RESPONSES IN FIBROSIS-DOMINANT ORGANS IN AGAVE-201 (Poster Area (Hall 7)) -  May 15, 2024 - Abstract #EHA2024EHA_3061;    
    P2
    In AGAVE-201, clinical activity in fibrosis-dominant organs is supported by clinician-reported changes in themajority of patients and patient-reported reductions in organ-specific symptom burden. Axatilimab had agenerally well-tolerated safety profile; opportunistic infections, which are typically common in patients withcGVHD under heavy immunosuppression, were infrequent with axatilimab.
  • ||||||||||  NOVEL EPIGENETIC BASED DIFFERENTIATION THERAPY FOR ACUTE MYELOID LEUKEMIA (Poster Area (Hall 7)) -  May 15, 2024 - Abstract #EHA2024EHA_1020;    
    Both compounds showed a mechanism of action different from other DACi, which was mediated bythe acetylation of non-histone proteins related to the enhancer-promoter chromatin regulatory complex. Thesecompounds represent a novel and promising approach for a differentiation-based therapy for testing in AMLpatients.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, revumenib (SNDX-5613) / Syndax Pharma
    CHARACTERIZATION OF IMMUNOPHENOTYPIC CHANGES FOLLOWING MENIN INHIBITION IN ACUTE MYELOID LEUKEMIA (Poster Area (Hall 7)) -  May 15, 2024 - Abstract #EHA2024EHA_985;    
    Acute myeloid leukemia following treatment with menin inhibitors frequently exhibits phenotypic shifts,manifested either by the state of differentiation (myeloid vs. monocytic) or patterns and/or intensity of antigenexpression. Awareness of these changes is crucial for an accurate assessment of measurable residual disease vsan ongoing response and a differentiation effect which requires further investigation.
  • ||||||||||  Actimab-A (lintuzumab-Ac225) / Actinium
    ANTILEUKEMIC ACTIVITY OF CD33-DIRECTED MUTATION-AGNOSTIC LINTUZUMAB-AC225 IN KMT2A MUTANT AML (Poster Area (Hall 7)) -  May 15, 2024 - Abstract #EHA2024EHA_939;    
    Combination of CD33-targeted radionuclide therapy with menin inhibitorsignificantly improves AML control, demonstrating that targeted radiotherapy approaches can augment menin-targeted therapy. Based on these findings, the combination of lintuzumab-Ac225 with mutation-targetedagents may enhance anti-leukemic response compared to single-agent approaches.
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS
    Enrollment change, Metastases:  Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (clinicaltrials.gov) -  May 3, 2024   
    P2,  N=143, Completed, 
    Based on these findings, the combination of lintuzumab-Ac225 with mutation-targetedagents may enhance anti-leukemic response compared to single-agent approaches. N=101 --> 143